IV 
119TH CONGRESS 
1ST SESSION 
H. RES. 209 
Expressing support for the designation of April 5, 2025, as ‘‘Barth Syndrome 
Awareness Day’’. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 10, 2025 
Mr. TONKO (for himself, Mr. BILIRAKIS, Ms. MATSUI, Mr. NORMAN, Mrs. 
TRAHAN, Mr. WILSON of South Carolina, and Mr. AUCHINCLOSS) sub-
mitted the following resolution; which was referred to the Committee on 
Energy and Commerce 
RESOLUTION 
Expressing support for the designation of April 5, 2025, 
as ‘‘Barth Syndrome Awareness Day’’. 
Whereas Barth syndrome is a rare, life-threatening, genetic 
disorder which primarily affects males; 
Whereas Barth syndrome is caused by a mutation in the 
tafazzin gene (TAFAZZIN, also called G4.5), resulting in 
an inborn error of phospholipid metabolism, affecting 
many systems of the body; 
Whereas Barth syndrome is a multisystem disorder with 
characteristics including abnormalities of heart and skel-
etal muscle, low levels of certain white blood cells called 
neutrophils that help to fight bacterial infections, and 
delays in growth; 
VerDate Sep 11 2014 
01:22 Mar 11, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR209.IH
HR209
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 209 IH 
Whereas with probably fewer than 10 new Barth infants 
identified each year in the United States, the incidence 
of Barth syndrome is likely only 1 in every 300,000 to 
400,000 births and could be as few as 1.5 in 1 million; 
Whereas globally there are approximately 300 individuals di-
agnosed with Barth syndrome, and, in the United States, 
there are fewer than 150 individuals diagnosed with 
Barth syndrome; 
Whereas Barth syndrome can be fatal in childhood due to 
heart failure or uncontrollable infection, with approxi-
mately 50 percent of deaths due to Barth syndrome oc-
curring within the first year of life and 85 percent before 
the fifth year of life; 
Whereas individuals with Barth syndrome who survive to 
adulthood often have a severely limited life expectancy; 
Whereas individuals with Barth syndrome, like many other 
rare disorders, experience challenges with obtaining a di-
agnosis, limited treatment options, and difficulty finding 
and accessing treatment centers and physicians with ex-
pertise in Barth syndrome; 
Whereas because the disorder affects multiple systems of the 
body, a patient with Barth syndrome often requires ac-
cess to care from experts across a range of medical spe-
cialties; 
Whereas the Barth Syndrome Clinic at Kennedy Krieger In-
stitute is the only interdisciplinary clinic dedicated to the 
diagnosis and treatment of Barth syndrome in the United 
States; 
Whereas, to date, there is no treatment for Barth syndrome 
that is approved by the Food and Drug Administration 
(FDA); 
VerDate Sep 11 2014 
01:22 Mar 11, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR209.IH
HR209
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 209 IH 
Whereas there is a critical need for research and development 
to advance treatments for Barth syndrome; 
Whereas, as a result of the Orphan Drug Act, there have 
been important advances in research on and treatment 
for rare diseases, including development efforts in Barth 
syndrome; 
Whereas the FDA established the Accelerated Approval Path-
way in 1992 and Congress codified the pathway in 2012; 
Whereas the Accelerated Approval Pathway is an important 
pathway for rare and ultrarare diseases as it allows for 
‘‘earlier approval of drugs that treat serious conditions, 
and fill an unmet medical need . . .’’; 
Whereas Congress and the FDA have affirmed the impor-
tance of incorporating the patient perspective throughout 
the drug review process through the FDA’s Patient-Fo-
cused Drug Development program; 
Whereas the Barth Syndrome Foundation, a nonprofit orga-
nization established in 2000 to accelerate progress 
through collaboration between families and scientists, is 
dedicated to educating, advancing treatments, and find-
ing a cure for Barth syndrome; 
Whereas the Barth Syndrome Foundation sponsors ‘‘Barth 
Syndrome Awareness Day’’ in the United States to in-
crease public awareness and generate additional support 
for Barth syndrome; and 
Whereas ‘‘Barth Syndrome Awareness Day’’ is expected to be 
observed in the United States for years to come, pro-
viding hope and information for patients, caregivers, and 
families around the country: Now, therefore, be it 
Resolved, That the House of Representatives— 
VerDate Sep 11 2014 
01:22 Mar 11, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR209.IH
HR209
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 209 IH 
(1) supports the designation of ‘‘Barth Syn-
drome Awareness Day’’; and 
(2) recognizes the importance of, with respect 
to Barth syndrome— 
(A) improving awareness; 
(B) encouraging accurate and early diag-
nosis; 
(C) advancing research; 
(D) 
developing 
new 
treatments, 
diagnostics, and cures; and 
(E) identifying regulatory pathways for 
drug development of ultrarare diseases like 
Barth syndrome. 
Æ 
VerDate Sep 11 2014 
01:22 Mar 11, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR209.IH
HR209
kjohnson on DSK7ZCZBW3PROD with $$_JOB